DE3854387T2 - Inclusion complex of nicardipine or its hydrochloride with beta-cyclodextrin, a process for producing the same and a delayed-action pharmaceutical preparation containing the same. - Google Patents

Inclusion complex of nicardipine or its hydrochloride with beta-cyclodextrin, a process for producing the same and a delayed-action pharmaceutical preparation containing the same.

Info

Publication number
DE3854387T2
DE3854387T2 DE3854387T DE3854387T DE3854387T2 DE 3854387 T2 DE3854387 T2 DE 3854387T2 DE 3854387 T DE3854387 T DE 3854387T DE 3854387 T DE3854387 T DE 3854387T DE 3854387 T2 DE3854387 T2 DE 3854387T2
Authority
DE
Germany
Prior art keywords
same
nicardipine
cyclodextrin
hydrochloride
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE3854387T
Other languages
German (de)
Other versions
DE3854387D1 (en
Inventor
Breda Husu
Jenny Milovac
Zdravko Kopitar
Branko Huc
Janko Zmitek
Peter Prof Bukovec
Mirjan Zorz
Boris Rusjakovski
Polona Cvelbar
Zdenka Jerala-Strukelj
Bojan Kofler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lek Pharmaceuticals dd
Original Assignee
Lek Pharmaceuticals and Chemical Co dd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Pharmaceuticals and Chemical Co dd filed Critical Lek Pharmaceuticals and Chemical Co dd
Application granted granted Critical
Publication of DE3854387D1 publication Critical patent/DE3854387D1/en
Publication of DE3854387T2 publication Critical patent/DE3854387T2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
DE3854387T 1988-01-18 1988-12-28 Inclusion complex of nicardipine or its hydrochloride with beta-cyclodextrin, a process for producing the same and a delayed-action pharmaceutical preparation containing the same. Expired - Fee Related DE3854387T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
YU8288A YU45837B (en) 1988-01-18 1988-01-18 PROCEDURE FOR PREPARATION OF THE NEW NICARDIPINE INCLUSION COMPLEX OZ. ITS HYDROCHLORIDE WITH BETA-CYCLODEXTRIN

Publications (2)

Publication Number Publication Date
DE3854387D1 DE3854387D1 (en) 1995-10-05
DE3854387T2 true DE3854387T2 (en) 1996-04-11

Family

ID=25548253

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3854387T Expired - Fee Related DE3854387T2 (en) 1988-01-18 1988-12-28 Inclusion complex of nicardipine or its hydrochloride with beta-cyclodextrin, a process for producing the same and a delayed-action pharmaceutical preparation containing the same.

Country Status (6)

Country Link
US (1) US5079237A (en)
EP (1) EP0324982B1 (en)
JP (1) JPH0780849B2 (en)
DE (1) DE3854387T2 (en)
SI (1) SI8810082A8 (en)
YU (1) YU45837B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198226A (en) * 1986-01-30 1993-03-30 Syntex (U.S.A.) Inc. Long acting nicardipine hydrochloride formulation
US4940556A (en) * 1986-01-30 1990-07-10 Syntex (U.S.A.) Inc. Method of preparing long acting formulation
US5206025A (en) * 1989-05-24 1993-04-27 Rhone-Poulenc Sante Porous pharmaceutical form and its preparation
TW282399B (en) * 1990-05-25 1996-08-01 Takeda Pharm Industry Co Ltd
ATE135214T1 (en) * 1992-02-17 1996-03-15 Siegfried Ag Pharma DOSAGE FORMS WITH EXTENDED RELEASE
IL104192A (en) * 1992-02-17 1998-01-04 Siegfried Ag Pharma Pharmaceutical dosage forms having prolonged release rate of zero order of the active ingredient
AT399718B (en) * 1992-04-16 1995-07-25 Lek Tovarna Farmacevtskih INCLUSION COMPLEXES OF OPTICALLY ACTIVE AND RACEMIC 1,4-DIHYDROPYRIDINES WITH METHYL-BETA-CYCLODEXTRIN OR OTHER CYCLODEXTRINE DERIVATIVES, A METHOD FOR THE PRODUCTION OF OPTICALLY ACTIVE DIHYDROPYRIDE-DOMETHYL-DOMETHYL-DOMETHYL-DOMETHYL POWERS
US7060498B1 (en) 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
US7157446B2 (en) * 2003-05-02 2007-01-02 Bristol Myers Squibb Company Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol
BRPI0600636A (en) * 2006-02-03 2007-10-30 Univ Minas Gerais process for formulations of angiotensin converting enzyme inhibitors and product
KR20090037388A (en) * 2006-04-18 2009-04-15 이케이알 테라퓨틱스, 인코포레이티드 Pre-mixed, ready-to-use iv bolus compositions and methods of use
KR100900928B1 (en) * 2007-06-05 2009-06-08 연세대학교 산학협력단 CaRma1H1 gene increasing plant stress resistance and transgenic plants transformed by CaRma1H1 gene
KR100877188B1 (en) * 2007-06-29 2009-01-07 한국원자력연구원 The process method of cosmetics composition from natural material by processing proton beam for skin whitening
ES2332168B1 (en) * 2008-04-30 2010-10-27 Consejo Superior De Investigaciones Cientificas (Csic) (75%) PSEUDOPOLIMORFICA FORM OF NICARDIPINE HYDROCLORIDE, PROCEDURE FOR PREPARATION AND FORMULATION CONTAINING IT.
JP5552400B2 (en) * 2010-09-07 2014-07-16 東亜薬品株式会社 Granules masking bitterness and unpleasant taste of herbal medicines and intraoral quick disintegrating tablets
CA2837232A1 (en) * 2011-06-03 2012-12-06 Ratiopharm Gmbh Pharmaceutical composition comprising dapagliflozin and cyclodextrin

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1455502A (en) * 1973-02-20 1976-11-10 Yamanouchi Pharma Co Ltd 1,4-dihydropyridine derivatives
JPS5486607A (en) * 1977-12-23 1979-07-10 Yoshinobu Nakai Solid pharmaceutical composition
HU176215B (en) * 1978-01-27 1981-01-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing a cyclodextrin-indomethacin inclusion complex with a ratio of at about 2:1
JPS5948810B2 (en) * 1980-03-22 1984-11-29 山之内製薬株式会社 Composition for nicardipine long-acting preparation
JPS5634618A (en) * 1979-08-30 1981-04-06 Ota Seiyaku Kk Production of flurbiprofen preparation
DE3270055D1 (en) * 1981-01-23 1986-04-30 Wellcome Found Chemical complex
JPS58116414A (en) * 1981-12-23 1983-07-11 Yamanouchi Pharmaceut Co Ltd Composition for pharmaceutical of prolonged release containing nicardipine and preparation thereof
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
JPS58213712A (en) * 1982-06-07 1983-12-12 Nikken Kagaku Kk Pp-1466-containing pharmaceutical preparation having prolonged effect
JPS5920230A (en) * 1982-07-19 1984-02-01 チバ−ガイギ−・アクチエンゲゼルシヤフト Drug containing piruprophen
JPS59152320A (en) * 1983-02-17 1984-08-31 Takeda Chem Ind Ltd Aqueous pharmaceutical preparation
DE3329517A1 (en) * 1983-08-16 1985-02-28 Hoechst Ag, 6230 Frankfurt INCLUDING COMPOUND OF N, N-DIMETHYL-2-CHLORINE-5- (3-METHYL-2- (PHENYLIMINO) -4-THIAZOLIN-4-YL) PHENYLSULFONAMIDE, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
JPS60246313A (en) * 1984-05-22 1985-12-06 Yamanouchi Pharmaceut Co Ltd Injection of nicardipine hydrochloride and its preparation
JPS61191623A (en) * 1985-02-20 1986-08-26 Green Cross Corp:The Easily absorbable medicinal composition
HU199444B (en) * 1985-09-10 1990-02-28 Chinoin Gyogyszer Es Vegyeszet Process for producing 7-isopropoxy-isoflavone-cyclodextrene inclusion complex and pharmaceutical compositions therefrom
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
YU43290B (en) * 1986-11-13 1989-06-30 Lek Tovarna Farmacevtskih Process for preparing inclusioned complex of ibuproxane with beta-cyclodextrine
JPH0819004B2 (en) * 1986-12-26 1996-02-28 日清製粉株式会社 Sustained-release pharmaceutical preparation
JP2603240B2 (en) * 1987-03-09 1997-04-23 バイエル薬品株式会社 Dihydropyridine-hydroxypropylcyclodextrin inclusion complex

Also Published As

Publication number Publication date
JPH0780849B2 (en) 1995-08-30
DE3854387D1 (en) 1995-10-05
SI8810082A8 (en) 1995-12-31
YU45837B (en) 1992-07-20
JPH02705A (en) 1990-01-05
YU8288A (en) 1989-12-31
EP0324982A1 (en) 1989-07-26
EP0324982B1 (en) 1995-08-30
US5079237A (en) 1992-01-07

Similar Documents

Publication Publication Date Title
DE3854387D1 (en) Inclusion complex of nicardipine or its hydrochloride with beta-cyclodextrin, a process for producing the same and a delayed-action pharmaceutical preparation containing the same.
DE68903120T2 (en) METHOD FOR THE PRODUCTION OF CYCLIC SULFATES.
DE68922339D1 (en) Hard transparent resins and process for their production.
DE3787703D1 (en) Inclusion complex of ibuproxam with beta-cyclodextrin, production process and pharmaceutical preparation containing this inclusion complex.
DE69007714T2 (en) Pharmaceutical preparation with an anti-tumor effect and process for its manufacture.
DE59003791D1 (en) Process for the preparation of 1,3,3-trimethyl-5-oxo-cyclohexane-carbonitrile.
DE59200799D1 (en) Process for the preparation of multinuclear aromatic polyamines.
DE69012650T2 (en) Piperidine derivative, process for its preparation and pharmaceutical composition containing the same.
DE59200828D1 (en) Process for the preparation of multinuclear aromatic polyamines.
DE68922042T2 (en) Process for the production of titanium oxide.
DE69006911D1 (en) Process for the preparation of 3,4-dichloroaniline.
DE68908162T2 (en) Process for the production of ceramic products, in particular ceramic springs.
DE68908464D1 (en) NEEDLE SHAPED TITANIUM DIOXIDE PARTICLES AND METHOD FOR THE PRODUCTION THEREOF.
DE3673822D1 (en) BENZOFURAN-2-YL-IMIDAZOLES WITH PHARMACEUTICAL EFFECT, THEIR SALTS AND RELEVANT PROCESS FOR THEIR PRODUCTION.
DE69011046T2 (en) Pyridine derivatives, manufacturing processes and pharmaceutical compositions.
DE69007245D1 (en) Aminobutanol derivatives and process for the preparation of 3-pyrrolidinol from them.
DE59004509D1 (en) Process for the production of TiO2 pigments.
DE68922275T2 (en) Process for the preparation of monochloroacetaldehyde trimer.
DE69009394D1 (en) Process for the preparation of 3-cyano-3,5,5-trimethyl-1-cyclohexanone.
DE3670491D1 (en) PYRAZINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS WITH THESE.
DE3783728D1 (en) SAFE PESTICIDAL RESIN COMPOSITIONS FOR COMBATING SOIL-BASED DISEASES AND METHOD FOR THE PRODUCTION THEREOF.
DE58905605D1 (en) Process for the preparation of cyclic ureas.
DE69013403T2 (en) Polypeptide with thrombin inhibiting activity and process for its production.
DE69009651D1 (en) Process for the preparation of 3,4-dihydrocumarin derivatives.
DE68922361T2 (en) Process for the preparation of 2,6-naphthalenedicarboxylic acid.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee